Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002395082 | SCV002703265 | pathogenic | Cardiovascular phenotype | 2021-02-25 | criteria provided, single submitter | clinical testing | The p.C55* pathogenic mutation (also known as c.165C>A), located in coding exon 2 of the JAG1 gene, results from a C to A substitution at nucleotide position 165. This changes the amino acid from a cysteine to a stop codon within coding exon 2. This mutation was identified in an individual with a clinical diagnosis of Alagille syndrome (Warthen DM et al. Hum. Mutat., 2006 May;27:436-43). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |